Day: April 1, 2024

On 01 April 2024 the merger of Coop Pank AS (Coop Pank) and Coop Finants AS was entered into the Estonian Commercial Register. With the entry, the merger has been completed. As a result of the merger, Coop Pank is the legal successor of Coop Finants AS and Coop Finants AS was deleted from the Estonian Commercial Registry. With registration of the merger in the Estonian Commercial Registry, all the assets, rights and obligations of Coop Finants AS were transferred to Coop Pank. The balance sheet date of the merger was 1 October 2023. Since it is an intragroup merger, it does not have an impact on the consolidated financial position and rights and obligations of Coop Pank’s group. Earlier information announced by Coop Pank about the merger is available here and here. Additional information:Paavo TruuCFOPhone: +372 5160 231 E-mail: paavo.truu@cooppank.ee...

The Supervisory Board of AS Ekspress Grupp approved the group’s audited annual report 2023 and submits it to the General Meeting of Shareholders for approval. The financial results for 2023 remain unchanged compared to the preliminary disclosure on 16th February 2024. In 2023, the consolidated audited sales revenue of AS Ekspress Grupp totalled EUR 73.1 million which increased by 14% compared to 2022. Group’s consolidated audited net profit for 2023 totalled EUR 3.4 million. Digital revenues increased by 21% year-over-year and the share of digital revenues was 83% of the group’s total revenue. AS Ekspress Grupp audited annual report for 2023 is published in accordance with the European Single Electronic Format (ESEF) requirements as an XHTML file and as a PDF file. The Group’s primary statements and notes to statements are labelled...

New name expresses the Company’s vision to lead the next era of medicine – from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing medicines, by investing in science and technology Sosei Group and its subsidiaries, Heptares Therapeutics and Idorsia Pharmaceuticals Japan and Korea, have all been renamed under the Nxera Pharma brandTokyo, Japan and Cambridge, UK, 1 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce the launch of its new company name, having received approval at the 34th Ordinary General Meeting of Shareholders held on 27 March 2024. The Company’s new website can be found at www.nxera.life   The Group name and those of its subsidiaries have changed as follows:Old...